300757:SZSERobotechnik Intelligent Technology Co., Ltd. Class A Analysis
Data as of 2026-06-14 - not real-time
CN¥600.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
RoboTechnik is trading well above its short‑term moving averages, indicating a bullish price bias, but the MACD histogram has turned negative, suggesting weakening momentum.
The stock’s valuation is dramatically out of line with its fundamentals – the DCF fair value is a fraction of the current price, the price‑to‑book multiple is extremely high, and earnings are negative despite rapid revenue growth. These contradictions, combined with a modest beta, very high short‑term volatility, and a dividend that is not supported by earnings, point to substantial upside risk of a correction. Investors should weigh the strong top‑line growth against the deep earnings gaps, heavy debt load, and unsustainable payout before deciding on exposure.
The stock’s valuation is dramatically out of line with its fundamentals – the DCF fair value is a fraction of the current price, the price‑to‑book multiple is extremely high, and earnings are negative despite rapid revenue growth. These contradictions, combined with a modest beta, very high short‑term volatility, and a dividend that is not supported by earnings, point to substantial upside risk of a correction. Investors should weigh the strong top‑line growth against the deep earnings gaps, heavy debt load, and unsustainable payout before deciding on exposure.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- bearish MACD histogram despite bullish price position
- extreme valuation gap relative to DCF and book value
- negative earnings and unsustainable dividend
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- robust revenue growth trajectory
- persistent operating losses and high debt burden
- volatile price action with limited downside protection
Long Term
> 3 yearsCautious
Model confidence: 6/10
Key Factors
- fundamentally weak profitability and cash conversion
- overextended valuation that could trigger a correction
- exposure to Chinese industrial cycle and policy shifts
Key Metrics & Analysis
Financial Health
Revenue Growth69.30%
Profit Margin-7.78%
ROE-6.02%
ROA-1.61%
Debt/Equity87.88
P/B Ratio61.9
Op. Cash FlowCN¥248.2M
Free Cash FlowCN¥-78257608
Industry P/E30.6
Technical Analysis
TrendBullish
RSI51.1
SupportCN¥520.71
ResistanceCN¥714.00
MA 20CN¥613.14
MA 50CN¥542.57
MA 200CN¥344.65
MACDBearish
VolumeStable
Fear & Greed Index89.86
Valuation
Fair ValueCN¥31.18
Target PriceCN¥788.00
Upside/Downside31.33%
GradeOvervalued
TypeGrowth
Dividend Yield0.02%
Risk Assessment
Beta0.31
Volatility79.25%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.